In an advance for precision oncology, the largest published study to date on molecular residual disease (MRD) detection in stage 3 colon cancer has demonstrated the prognostic capabilities of Guardant ...
2d
A Look At Guardant Health (GH) Valuation As New ctDNA Study Supports Guardant Reveal In Colon Cancer
Guardant Health (GH) is back in focus after it and major research partners published the largest study so far on circulating ...
PRIMETIMER on MSN
We are heartbroken: Guardant Health mourns brand ambassador James Van Der Beek’s passing, donates $25,000 to actor’s fundraiser
James Van Der Beek, who was suffering from colorectal cancer, was a spokesperson for the company and its Shield blood test.
Guardant Health stock is back in focus after a major institutional investor reduced its position by nearly one-third. Principal Financial Group lowered its holdings during the latest quarter, while ...
PALO ALTO, Calif., November 05, 2025--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health") (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering ...
Guardant Health hasn't scheduled its Q4 update yet but will likely report results by Feb. 19, 2026. The precision oncology company has had a lot of good news recently. However, the investment thesis ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation’s most widely used comprehensive ...
Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif.
I was a little late to the party in buying Guardant Health (GH 0.75%). After watching the stock soar during the latter part of 2018 and the first half of 2019, I finally jumped in to scoop up shares ...
Craig-Hallum used to like Exact Sciences stock -- but now it likes Guardant Health even more. Five years from now, the investment banker thinks Guardant's annual revenue could be three times what it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results